EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study

Jaehyun Bae iD, Minyoung Lee iD, Hyung Woo Kim, Jung Tak Park, Seung Hyeok Han iD, Byung-Wan Lee iD, Eun Seok Kang iD, Bong-Soo Cha iD, Tae-Hyun Yoo, Yong-Ho Lee iD

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6245-6253

DOI: 10.1111/dom.70816 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 04.05.2026. Verfasst von Jaehyun Bae und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hall…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Hyperkalemia, Mineralocorticoid Receptor Antagonists, Naphthyridines. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Korean Government (MSIT), The Ministry of Health & Welfare, Republic of Korea, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Finerenone is approved for the treatment of diabetic kidney disease (DKD), but real‐world evidence remains limited. We evaluated the effectiveness and safety of finerenone in routine clinical practice. Materials and Methods This retrospective observational study included patients with DKD who were prescribed finerenone. Effectiveness was assessed by measuring changes in urine protein‐to‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) over the 6‐month period following initiation of finerenone. Changes in estimated glomerular filtration rate, blood pressure, potassium levels, renin, and aldosterone were also monitored.

Results

A total of 404 patients with DKD were analysed. After 6 months of finerenone treatment, UPCR and UACR decreased substantially, with mean within‐subject changes of −820.2 ± 1528.3 and −606.4 ± 1119.6 mg/g, respectively. 59.9% of patients achieved a ≥ 30% reduction in UPCR from baseline. Patients who were older, had lower baseline potassium levels, and received a higher mean daily dose of finerenone exhibited a more favourable response to finerenone. The mean increase in potassium levels was 0.3 mEq/L at 6 months, and the treatment discontinuation rate due to hyperkalemia was 5.4%. The aldosterone‐to‐renin ratio showed a modest decrease at 3 months (mean within‐subject change, −3.79 ± 13.76 ng/dL per ng/mL/h), with borderline statistical significance.

Conclusions

Finerenone treatment was associated with a significant reduction in proteinuria in patients with DKD. The safety profile was comparable to that reported in previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesHyperkalemiaMineralocorticoid Receptor AntagonistsNaphthyridinesProteinuriaAgedFemaleHumansMaleMiddle AgedAlbuminuriaBlood PressureCreatinineGlomerular Filtration RatePotassiumRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Finerenonediabetic nephropathiesproteinuria

Substanzen

CreatininefinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesPotassium

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Republic of Korea.
  • Department of Internal Medicine, Institute for Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Yonsei Institute for Digital Health, Yonsei University, Seoul, Republic of Korea.

ORCID-Profile: Jaehyun Bae, Minyoung Lee, Seung Hyeok Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-Ho Lee

Förderung

  • Korean Government (MSIT)
  • The Ministry of Health & Welfare, Republic of Korea
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Bae, J., Lee, M., Kim, H. W., Park, J. T., Han, S. H., Lee, B. W., Kang, E. S., Cha, B. S., Yoo, T. H., & Lee, Y. H. (2026). Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study. Diabetes, Obesity and Metabolism, 28(7), 6245-6253. https://doi.org/10.1111/dom.70816

Vancouver

Bae J, Lee M, Kim HW, Park JT, Han SH, Lee BW, et al. Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study. Diabetes, Obesity and Metabolism. 2026;28(7):6245-6253. doi:10.1111/dom.70816

BibTeX
@article{Bae2026,
  author = {Bae, Jaehyun and Lee, Minyoung and Kim, Hyung Woo and Park, Jung Tak and Han, Seung Hyeok and Lee, Byung-Wan and Kang, Eun Seok and Cha, Bong-Soo and Yoo, Tae-Hyun and Lee, Yong-Ho},
  title = {Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real‐World Observational Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6245--6253},
  doi = {10.1111/dom.70816}
}
Kostenlos starten →